Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview

Saudi Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 91-105

  Dajani, Asad ^a   Abuhammour, Adnan ^b  

^a Asad Dajani Specialized Center   (United Arab Emirates)

^b Abuhammour Medical Center   (United Arab Emirates)

Author keywords

Insulin sensitizers; liver protectors; Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; Ursodeoxycholic acid; Vitamin E

Indexed keywords

ACARBOSE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHOCYANIN; ANTIFIBROTIC AGENT; ANTILIPEMIC AGENT; ELAFIBRANOR; FOLIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; INSULIN SENSITIZING AGENT; LIVER PROTECTIVE AGENT; METRELEPTIN; OBETICHOLIC ACID; PIOGLITAZONE; PRADIGASTAT; PROBIOTIC AGENT; QUERCETIN; RESVERATROL; ROFLUMILAST; S ADENOSYLMETHIONINE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; VITAMIN D; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; ANTIDIABETIC AGENT; CHALCONE DERIVATIVE; CHENODEOXYCHOLIC ACID; PROPIONIC ACID DERIVATIVE;

ANTIOXIDANT ACTIVITY; ARTICLE; COFFEE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); ENDOPLASMIC RETICULUM STRESS; HUMAN; LIFESTYLE MODIFICATION; LIVER FIBROSIS; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; HEALTH CARE QUALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK REDUCTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CHALCONES; CHENODEOXYCHOLIC ACID; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPIONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; STANDARD OF CARE;

EID: 84962346000     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.178527     Document Type: Article

References (135)

1. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26(Suppl 1): 163-72
2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: Epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-33
3. Söderberg C, Stå l P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602
4. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-Alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-54
5. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-71
6. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-Alcoholic fatty liver disease (NAFLD): A systematic review and meta-Analysis of randomised trials. Diabetologia 2012; 55: 885-904
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-Alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-26
8. Babio N, Toledo E, Estruch R, Ros E, Martínez-González MA, Castañer O, et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 2014; 186: E649-57
9. Gasteyger C, Larsen TM, Vercruysse F, Astrup A. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr 2008; 87: 1141-7
10. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al.; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156-63
11. Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, et al.; Look AHEAD Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 2010; 59: 627-33
12. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44
13. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-6
14. European Medicine Agency. Xenical 120 mg Summary of Product Characteristics. Available from: http: //www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/000154/WC500058428.pdf. [Last accessed on 2015 Apr 19]
15. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: A future treatment by choice or by chance?. J Obes 2013; 2013: 839275
16. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-Alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; CD007340
17. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-402
18. D'Albuquerque LA, Gonzalez AM, Wahle RC, de Oliveira Souza E, Mancero JM, de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl 2008; 14: 881-5
19. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and non-Alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne) 2014; 5: 164
20. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-Alcoholic steatohepatitis. Lancet 2001; 358: 893-4
21. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44
22. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90
23. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011; 305: 1659-68
24. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404
25. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-Alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003; 1: 384-7
26. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84
27. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85
28. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-Alcoholic steatohepatitis -A systematic review andmeta analysis. J Hepatol 2011; 55: 1383-90
29. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106: 71-7
30. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-Alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-7
31. Horlander J, Kwo P. Atorvastatin for the treatment of NASH. Hepatology 1997; 26: 544A
32. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-8
33. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-Term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7
34. Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al.; San Diego Integrated NAFLD Research Consortium (SINC Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) Hepatology 2015 61 239-50
35. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000; 136: 734-8
36. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-Tocopherol in patients with non-Alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72
37. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2348-50
38. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5: 109-13
39. Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-Alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 2014; 5: 9-12
40. Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9: 265-70
41. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-Alcoholic fatty liver disease. Lipids Health Dis 2011; 10: 49
42. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9
43. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?. Adv Ther 2008; 25: 1141-74
44. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci 2011; 56: 564-8
45. Lugo-Baruqui A, Muñoz-Valle JF, Arévalo-Gallegos S, Armendáriz-Borunda J. Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. Hepatol Res 2009; 40: 95-104
46. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5
47. Gonciarz Z, Besser P, Lelek E, Gundermann KJ, Johannes KJ. Randomized placebo-controlled double-blind trial on 'essential' phospholipids in the treatment of fatty liver associated with diabetes. Med Chir Dig 1988; 17: 61-5
48. Arvind N, Savaikar P, Rajkumar JS. Therapy for NAFLD: A comparative study of essential phospholipids vs. ursodeoxycholic acid. Ind J Clin Pract 2006; 16: 21-4
49. Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AI. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol 2015.[Epub ahead of print]
50. Kajikawa S, Imada K, Takeuchi T, Shimizu Y, Kawashima A, Harada T, et al. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine-And choline-deficient diet. Dig Dis Sci 2011; 56: 1065-74
51. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-8
52. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147: 377-84.e1
53. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-Analysis. World J Gastroenterol 2013; 19: 6911-8
54. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-3
55. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-Alcoholic fatty liver disease: Which and when. Ann Hepatol 2013; 12: 357-63
56. Ikenaga N, Yoshida S, Liu SB, Chung J, Sverdlov D, Marshall D, et al. Targeting Lysyl Oxidase like 2 (LOXL2) Inhibits Collagen Cross-Linking and Accelerates Reversal of Pre-Established Liver Fibrosis. Hepatology 2013; 58: 219A-20A
57. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82.e1
58. Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs 2014; 23: 1441-8
59. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-Activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013; 58: 1941-52
60. DUR-928. Available from: http: //www.durect.com/wt/durect/page name/DUR-928. [Last accessed on 2015 May 25]
61. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013; 8: e75361
62. Harrison S. Galectin Therapeutics': Phase 1 Data Advances GR-MD-02 in to Phase 2 Clinical Development. Presented at AASLD Annual Meeting 2014. Available from: www.galactintherapeutics.com/releasedetail.cfm?ReleaseID=897897. [Last accessed on 2015 May 25]
63. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2085-91.e1
64. Regulus Reports First Quarter 2015 Financial Results and Recent Highlights. Available from: http: //www.researchviews.com/healthcare/pharma/infectiousdisease/NewsReport.aspx?Type=1andsector=Infectious DiseaseandArticleID=4571857. [Last accessed on 2015 May 25]
65. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 2015; 61: 1392-405
66. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009; 26: 893-907
67. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-Alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8
68. Mahady S. Therapies for nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) 2013; 9: 40-2
69. Xiao WH, Wang YR, Hou WF, Xie C, Wang HN, Hong TP, et al. The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. Int J Endocrinol 2013; 2013: 290734
70. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-Alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-5
71. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep 2013; 15: 305
72. Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr 2013; 5: 32
73. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: A molehill, an iceberg, or neither?. Hepatology 2008; 48: 662-9
74. Riche DM, Fleming JW, Malinowski SS, Black CA, Miller KH, Wofford MR. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Ann Pharmacother 2014; 48: 137-41
75. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 2010; 45: 445-50
76. Filippatos TD, Elisaf MS. Role of ezetimibe in non-Alcoholic fatty liver disease. World J Hepatol 2011; 30: 265-7
77. Shu X, Zhang L, Ji G. Vitamin E therapy in non-Alcoholic fatty liver disease. Int J Clin Med 2014; 5: 87-92
78. Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012; 15: 641-8
79. Mitchel EB, Lavine JE. Review article: The management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1155-70
80. Adams LA, Angulo P. Treatment of non-Alcoholic fatty liver disease. Postgrad Med J 2006; 82: 315-22
81. Mouzaki M, Allard J. Non-Alcoholic steatohepatitis: The therapeutic challenge of a global epidemic. Ann Gastroenterol 2012; 25: 207-17
82. Kotb MA. Molecular mechanisms of ursodeoxycholic Acid toxicity and side effects: Ursodeoxycholic Acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012; 13: 8882-914
83. Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-Alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7356-65
84. Liu J, Wang G, Jia Y, Xu Y. GLP-1 receptor agonists: Effects on the progression of non-Alcoholic fatty liver disease. Diabetes Metab Res Rev 2015; 31: 329-35
85. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6: 242-50
86. Zeng T, Zhang CL, Zhao XL, Xie KQ. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: A meta-Analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 2014; 26: 646-53
87. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-Analysis. World J Gastroenterol 2014; 20: 569-77
88. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-Angiotensin system: Implications for treatment. World J Hepatol 2012; 4: 327-31
89. Anstee QM, Day CP. S-Adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol 2012; 57: 1097-109
90. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010; 3: 121-37
91. Study to Investigate the Effects of Different Doses of S-Adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-Treated Matched Healthy Volunteers as Control Group (EXPO). Available from: https: //clinicaltrials.gov/ct2/show/NCT01754714?term=S-Adenosyl+Methionine+and+NAFLDandrank=1. [Last accessed on 2015 May 25]
92. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-62
93. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012; 7: e45425
94. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-Alcoholic fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013; 13: e7233
95. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-Alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 15518-31
96. Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015; 3: 5
97. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR α /δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008-14
98. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, et al. Dual peroxisome proliferator-Activated receptor α /δ agonist GFT505 improves hepatic and peripheral Insulin sensitivity in abdominally obese subjects. Diabetes Care 2013; 36: 2923-30
99. Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, et al. Serum vitamin B12 and folate levels in patients with non-Alcoholic fatty liver disease. Int J Food Sci Nutr 2012; 63: 659-66
100. Pearlman M, Loomba R. State of the art: Treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2014; 30: 223-37
101. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-Analysis: Vitamin D and non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 246-54
102. Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?. Hepatology 2013; 58: 1166-74
103. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-12
104. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: A randomised placebo-controlled trial. Eur J Endocrinol 2012; 167: 531-41
105. ClinicalTrials.gov, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LCQ908 in Patients with Severe Hypertriglyceridemia. Available from: http: //www.clinicaltrials.gov/ct2/show/study/NCT01146522. [Last accessed on 2013 Jun 1]
106. Stefano JT, de Oliveira CP, Corrê a-Giannella ML, de Lima VM, de SáSV, de Oliveira EP, et al. Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): Effects on peroxisome proliferator-Activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 2007; 52: 3448-54
107. Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): A randomized pilot study. Dig Dis Sci 2006; 51: 1183-9
108. Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int 2007; 27: 220-6
109. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: Relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004; 151: 483-9
110. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-Alcoholic fatty liver disease by activating AMP-Activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706
111. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-κ B activity in a murine model for treating non-Alcoholic fatty liver disease. Food Chem Toxicol 2014; 63: 166-73
112. Guo H, Li D, Ling W, Feng X, Xia M. Anthocyanin inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCζ . J Lipid Res 2011; 52: 908-22
113. Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev 2013; 2013: 145421
114. Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, González-Gallego J, et al. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 2012; 142: 1821-8
115. Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, et al. Quercetin improves insulin resistance and hepatic lipid accumulationin vitro in a NAFLD cell model. Biomed Rep 2013; 1: 71-6
116. Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 2013; 169: 1352-71
117. Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008; 55: 549-56
118. Hajiaghamohammadi AA, Miroliaee A, Samimi R, Alborzi F, Ziaee A. A comparison of ezetimibe and acarbose in decreasing liver transaminase in nonalcoholic fatty liver disease: A randomized clinical trial. Govaresh 2013; 18: 186-90
119. Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, et al. Long-Term combination therapy of ezetimibe and acarbose for non-Alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56
120. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, et al.; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014; 34: 1250-8
121. Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: A systematic review. Liver Int 2014; 34: 495-504
122. Buang Y, Wang YM, Cha JY, Nagao K, Yanagita T. Dietary phosphatidylcholine alleviates fatty liver induced by orotic acid. Nutrition 2005; 21: 867-73
123. Gundermann KJ, Kuenker A, Kuntz E, Droź dzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep, 2011. 63. p. 643-59
124. Yin D, Kong L. Observation for curative effect of essentiale in treatment of fatty liver caused by diabetes mellitus. Med J Q Ilu 2000; 15: 277-8
125. Du Q. Treatment of 52 cases with hepatic dysfunctional fatty liver with essentiale. Chin J Gastro Heap 2004; 13: 21-4
126. Padma L, Mukaddam Q, Trailokya A. An Observational Study of Essentiale-L in the treatment of Patients with Fatty Liver Disease. Indian J Clin Pract 2013; 23: 735-9
127. Sun C, Zheng X, Tan Z, Cui F, Zhang R, Zhang H. Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type-2 diabetes and non-Alcoholic fatty liver disease. Clinical Focus 2008; 23: 1272-3
128. Wu Y. Effective analysis of type 2 diabetic united adiposis hepatica with polyene phosphatidylcholine. J Tradit Chin Med 2009; 29: 41-2
129. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic Biol Med 2012; 52: 1658-65
130. Sas E, Grinevich V, Efimov O, Shcherbina N. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J Hepatol 2013; 58(Suppl 1): S549
131. Arvind N, Savaikar P, Rajkumar J. Therapy for NAFLD. A comparative study of essential phospholipids vs ursodeoxycholic acid. Indian J Clin Pract 2006; 16: 21-4
132. Zeng JT, Chen J. Clinical observation on the results in treatment of NAFLD with polyene phosphatidylcholine combined with Xuezhikang capsules. China Trop Med 2008; 8: 778-9
133. Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi M, Nounou MA. Essential phospholipids as a supportive adjunct to the management of patients with primary NAFLD and NAFLD associated with type 2 diabetes mellitus or hyperlipidaemia. Hepatol Int 2013; 7(Suppl 1): S1-754
134. Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon 2015; 11: 173-7
135. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: Past, present, future. Phytother Res 2010; 24: 1423-32